(±)-Felodipine-d5
(Synonyms: 非洛地平-D5) 目录号 : GC46289An internal standard for the quantification of felodipine
Cas No.:1242281-38-4
Sample solution is provided at 25 µL, 10mM.
(±)-Felodipine-d5 is intended for use as an internal standard for the quantification of (±)-felodipine by GC- or LC-MS. (±)-Felodipine is an inhibitor of L-type calcium channels.1 It induces relaxation of precontracted isolated porcine coronary artery segments (EC50 = 0.15 nM), which highly express L-type calcium channels.2 (±)-Felodipine is selective for L-type calcium channels over N-, R-, and P/Q-type channels at 10 µM, as well as the T-type Cav3.2 channel (IC50 = 6.8 µM).1,3 (±)-Felodipine preferentially inhibits L-type calcium channels in isolated rat portal vein over rat left ventricle (IC50s = 33.9 and 3,981 nM, respectively).4 It decreases mean arterial blood pressure and total peripheral resistance in a rabbit model of hypertension induced by renal artery ligation when administered intravenously at doses of 30 and 100 nmol/kg.5
1.Furukawa, T., Yamakawa, T., Midera, T., et al.Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytesJ. Pharmacol. Exp. Ther.291(2)464-473(1999) 2.Johnson, J.D., and Fugman, D.A.Calcium and calmodulin antagonists binding to calmodulin and relaxation of coronary segmentsJ. Pharmacol. Exp. Ther.226(2)330-334(1983) 3.Perez-Reyes, E., Van Deusen, A.L., and Vitko, I.Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: Block by antihypertensives, antiarrhythmics, and their analogsJ. Pharmacol. Exp. Ther.328(2)621-627(2009) 4.Ljung, B.Vascular selectivity of felodipine: Experimental pharmacologyJ. Cardiovasc. Pharmacol.15(Suppl 4)S11-S16(1990) 5.Bolt, G.R., and Saxena, P.R.Acute systemic and regional hemodynamic effects of felodipine, a new calcium antagonist, in conscious renal hypertensive rabbitsJ. Cardiovasc. Pharmacol.6(4)707-712(1984)
Cas No. | 1242281-38-4 | SDF | |
别名 | 非洛地平-D5 | ||
Canonical SMILES | CC1=C(C(C(C(OC([2H])([2H])C([2H])([2H])[2H])=O)=C(N1)C)C2=C(C(Cl)=CC=C2)Cl)C(OC)=O | ||
分子式 | C18H14Cl2D5NO4 | 分子量 | 389.3 |
溶解度 | Chloroform: soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5687 mL | 12.8436 mL | 25.6871 mL |
5 mM | 0.5137 mL | 2.5687 mL | 5.1374 mL |
10 mM | 0.2569 mL | 1.2844 mL | 2.5687 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet